MustGrow Biologics Corp. Announces Results of Shareholder Meeting
Saskatoon, Saskatchewan--(Newsfile Corp. - June 26, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the results of its 2025 annual meeting of shareholders (the "Meeting") held on June 26, 2025. At the Meeting, all director nominees listed in the...
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2025-06-26 6:15 PM EDT | MustGrow Biologics Corp.
Hemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - June 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces its Chairman, Peter Lacey, has provided the Company with a lead order for a non brokered private placement in the amount of $1,500,000 for Units at $0.10. Each Unit...
Biotechnology, Pharmaceuticals, Health
2025-06-26 9:00 AM EDT | Hemostemix Inc.
New CPT Codes for Totally Implantable Active Middle Ear Hearing Implants Go into Effect July 1, Unlocking New Opportunities for Envoy Medical
White Bear Lake, Minnesota--(Newsfile Corp. - June 26, 2025) - Envoy Medical, Inc. (NASDAQ: COCH), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announced that five Category III CPT codes for totally implantable active middle ear implants approved by the...
Biotechnology, Healthcare and Hospitals
2025-06-26 8:00 AM EDT | Envoy Medical, Inc.
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States
Fiscal year 2025 revenue of $108.3 million, record net income of $2.2 million, operating income of $8.2 million, and record Adjusted EBITDA* of $20.2 millionUS commercial launch of GRAFAPEX™ executed in February 2025, following swiftly on the FDA's approval in January 2025, with initial indicators supporting Medexus's confidence in the...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-25 6:15 PM EDT | Medexus Pharmaceuticals Inc.
InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it has entered into definitive agreements with a single institutional...
Biotechnology, Pharmaceuticals
2025-06-25 8:00 AM EDT | InMed Pharmaceuticals
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort
-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. - June 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer....
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-25 7:45 AM EDT | Phio Pharmaceuticals Corp.
PreveCeutical Announces Date for Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has scheduled its annual general and special meeting for August 15, 2025, at which the shareholders (the "PreveCeutical Shareholders") of the Company will be...
Biotechnology, Pharmaceuticals, Health
2025-06-25 7:00 AM EDT | PreveCeutical Medical Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Marlborough, Massachusetts--(Newsfile Corp. - June 24, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-24 7:45 AM EDT | Phio Pharmaceuticals Corp.
InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study
Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/GroSignificantly reduces levels of inflammasome marker, NLRP3, a key contributor to neurodegenerationReduces key pro-inflammatory markers, independent of amyloid beta or tau pathologyVancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or t
Biotechnology, Pharmaceuticals
2025-06-24 7:00 AM EDT | InMed Pharmaceuticals
PlasCred Circular Innovations Inc. Announces Extension of Strategic Private Placement Closing
Calgary, Alberta--(Newsfile Corp. - June 23, 2025) - PlasCred Circular Innovations Inc. (CSE: PLAS) (FSE: XV2) ("PlasCred" or the "Company"), a transformative leader in the advanced plastic waste recycling sector, is pleased to announce that it has extended the closing of its previously announced strategic non-brokered private placement (the "Offering")...
Technology, Biotechnology, Bioplastics
2025-06-23 8:55 AM EDT | PlasCred Circular Innovations Inc.
IR-MED Reports Positive Interim Results from U.S. Clinical Study of PressureSafe(TM) for Pressure Injury Assessment Across Diverse Skin Tones
PressureSafe™, IR-MED's lead product, demonstrated 94% sensitivity in assessing tissue at risk for pressure injuries prior to visible skin breakdownTechnology addresses longstanding disparities in skin assessment, particularly in patients with darker skin tonesResults presented at HCA Healthcare & Galen College of Nursing Research Day
Technology, Biotechnology, Healthcare and Hospitals, Health
2025-06-23 8:30 AM EDT | IR-MED, Inc.
Medicus Pharma Ltd. Announces Appointment of Andrew Smith as Chief Operating Officer
Philadelphia, Pennsylvania--(Newsfile Corp. - June 23, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the appointment of Andrew Smith as Chief Operating Officer. Andrew joins Medicus with over three decades of experience and is an accomplished C-suite professional with a successful track record...
Banking/Financial Services, Biotechnology, Investment Banking, Health
2025-06-23 7:30 AM EDT | Medicus Pharma Ltd.
Moss Genomics Announces Strategic Investment in Genomes.io
Vancouver, British Columbia--(Newsfile Corp. - June 19, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is pleased to announce that on June 18, 2025, it has entered into a non-binding term sheet for a strategic, non-controlling equity investment in Genomes.io Ltd. ("Genomes.io"), a UK-based...
2025-06-19 8:00 AM EDT | Moss Genomics Inc.
Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025
Denver, Colorado--(Newsfile Corp. - June 18, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that Psychedelic Science 2025 ("PS2025") - the world's largest international gathering focused on psychedelic research, biopharma, medicine, policy, and culture, hosted by the Multidisciplinary Associ
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-06-18 8:30 AM EDT | Psyence Biomedical Ltd.
Telo Genomics Initiate Clinical Trial for Minimal Residual Disease in Multiple Myeloma
Toronto, Ontario--(Newsfile Corp. - June 18, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through its proprietary 3D analysis of the genomic instability of telomeres, is pleased to announce that it has...
2025-06-18 8:30 AM EDT | Telo Genomics Corp.
NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
Vancouver, British Columbia--(Newsfile Corp. - June 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced the appointment of Randall Kaye, MD, to the role of Chief Medical Advisor. Dr. Kaye, a current member of NervGen's Board of Directors...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-18 7:30 AM EDT | NervGen Pharma Corp.
Relive Greens from The Root Brands: The Key to Gut Health and Digestion in 2025
Franklin, Tennessee--(Newsfile Corp. - June 17, 2025) - As gut health and digestion take center stage in 2025's health and wellness trends, The Root Brands proudly presents Relive Greens as the ultimate solution to support a healthy digestive system. With 83% of Americans recognizing the critical role of gut health...
Biotechnology, Food/Beverages, Health
2025-06-17 8:01 PM EDT | DRC Ventures
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 26, 2025 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2025. Medexus...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-17 5:00 PM EDT | Medexus Pharmaceuticals Inc.
Hemostemix Closes Private Placement of $469,366
Calgary, Alberta--(Newsfile Corp. - June 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces the closing of a non brokered private placement with in the amount of CAD $469,366 by the issuance of 3,911,385 Common Shares at CAD $0.12 each, subject to...
Biotechnology, Pharmaceuticals, Health
2025-06-17 8:41 AM EDT | Hemostemix Inc.
Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements
New York, New York--(Newsfile Corp. - June 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that it has received formal notification from the Nasdaq Hearings Panel confirming that the Company has regained compliance with all applicable Nasdaq continued listing requirements. This confirmation follows...
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-06-17 8:00 AM EDT | Psyence Biomedical Ltd.